Having trouble accessing articles? Reset your cache.

D&D raises $137M to fund inflammation tech out of JHU

South Korea’s D&D Pharmatech raised $137.1 million in a series B round to push forward the pipelines of its trio of inflammation-focused subsidiaries.

Founded in 2014, D&D Pharmatech Co. Ltd. (Gyeonggi-do, South Korea) is the parent company of a series of wholly owned subsidiaries

Read the full 436 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers